The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).
Robert B. Montgomery
Consultant or Advisory Role - Ipsen
Research Funding - Cougar Biotechnology; Tokai
Mario A. Eisenberger
Consultant or Advisory Role - Astellas Pharma; Millennium; Sanofi
Honoraria - Bristol-Myers Squibb; Millennium
Research Funding - Astellas Pharma; Sanofi ; Tokai
Matthew Rettig
No relevant relationships to disclose
Franklin Chu
No relevant relationships to disclose
Roberto Pili
Research Funding - Tokai
Joe Stephenson
Research Funding - Tokai
Nicholas J. Vogelzang
Consultant or Advisory Role - Amgen; Celgene; Cougar Biotechnology; GlaxoSmithKline; Takeda
Honoraria - Bayer; Cougar Biotechnology; Genentech; Johnson & Johnson; Veridex
Research Funding - Algeta; Cougar Biotechnology; Johnson & Johnson; Novartis; Pfizer; Takeda; Tokai
Jodie Morrison
Employment or Leadership Position - Tokai
Stock Ownership - Tokai
Mary-Ellen Taplin
Research Funding - GlaxoSmithKline; Johnson & Johnson; Tokai